Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T12:45:13.015Z.
Calculation as of: 2026-10-06T12:45:13.015Z.
Quote observation: 2026-10-05T20:00:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 374a47b91f4df6a230cb26954d8d957a3b546ee3094b4b70ca7ed529159f4796
PEG RATIO
N/A
ABVC BioPharma, Inc.
Market Cap
$25.48M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| ABVC BioPharma, Inc. (ABVC) | $25.48M | N/A |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $27.31M | N/A |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | N/A |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | N/A |
| CervoMed Inc. (CRVO)vs › | $30.65M | N/A |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A |
| Cosmos Health Inc. (COSM)vs › | $18.82M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
